Pacer Advisors
ARCT icon

Pacer Advisors’s Arcturus Therapeutics ARCT Stock Holding History

Pacer Advisors’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-444
Closed -$10.8K – 2569
2024
Q2 		$10.8K Sell
444
-287
-39% -$8.7K ﹤0.01% 3535
2024
Q1 		$24.7K Buy
+731
New +$25.9K ﹤0.01% 3403
2021
Q2 		– Sell
-1,578
Closed -$65K – 1417
2021
Q1 		$65K Buy
1,578
+332
+27% +$19.8K ﹤0.01% 1401
2020
Q4 		$54K Buy
+1,246
New +$84.4K ﹤0.01% 1408

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pacer Advisors's ARCT Position: Q3 2024 in Review

Pacer Advisors sold out of Arcturus Therapeutics (ARCT) in Q3 2024, closing a stake of 444 shares — an estimated $10.8K sold.

Pacer Advisors first reported a position in ARCT in Q4 2020 and held it in 4 quarters. The position peaked at $65K in Q1 2021. 164 funds tracked by Wall St. Rank hold ARCT as of Q3 2024.

  • Pacer Advisors reported no remaining Arcturus Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Pacer Advisors sold 444 Arcturus Therapeutics shares in Q3 2024, an estimated $10.8K.
  • Pacer Advisors first reported a position in Arcturus Therapeutics in Q4 2020 and held it in 4 quarters.
  • Pacer Advisors's Arcturus Therapeutics position peaked at $65K in Q1 2021.
  • 164 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2024.

Based on Pacer Advisors's 13F filing for Q3 2024, filed 12 Nov 2024.